<DOC>
	<DOCNO>NCT00666562</DOCNO>
	<brief_summary>Green tea extract contain ingredient may slow growth certain cancer . It yet know whether green tea extract effective placebo give surgery treat patient bladder . This randomized phase II trial study green tea extract see well work compare placebo give surgery treat patient nonmetastatic bladder cancer .</brief_summary>
	<brief_title>Green Tea Extract Treating Patients With Nonmetastatic Bladder Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES I . To compare level epigallocatechin-3-gallate ( EGCG ) nonmalignant bladder tissue patient bladder cancer treat oral polyphenon E 800 mg EGCG polyphenon E 1200 mg EGCG daily 14-28 day . SECONDARY OBJECTIVES : I . To compare level EGCG nonmalignant versus malignant bladder tissue sample patient . II . To examine dose-response modulation surrogate intermediate endpoint biomarkers ( e.g. , Proliferating Cell Nuclear Antigen [ PCNA ] , Matrix Metallopeptidase 2 [ MMP2 ] , clusterin , Vascular endothelial Growth Factor [ VEGF ] , p27 , ODC ) malignant nonmalignant sample bladder tissue patient administration polyphenon E. III . To correlate EGCG level sample serum , urine , tissue patient . IV . To examine level catechin ( i.e. , epicatechin , epicatechin gallate , epigallocatechin ) find polyphenon E sample serum , urine , tissue patient . V. To compare metabolism EGCG Catechol-O-Methyltransferase ( COMT ) Uridinediphosphate-Glucuronosyltransferase ( UGT ) relation pharmacogenetic polymorphism COMT UGT sample serum , urine , tissue patient . VI . To examine change serum Insulin Growth Factor 1 ( IGF-1 ) IGFBP-3 level administration polyphenon E patient . OUTLINE : This multicenter study . Patients stratify accord tumor site disease invasiveness ( invasive v noninvasive ) . Patients randomize 1 3 treatment arm . Arm I : Patients receive six oral placebo capsule daily 14-28 day absence unacceptable toxicity . Arm II : Patients receive four oral polyphenon E capsule two oral placebo capsule daily 14-28 day absence unacceptable toxicity . Arm III : Patients receive six oral polyphenon E capsule daily 14-28 day absence unacceptable toxicity . After completion study treatment , patient undergo trans-urethral resection bladder tumor cystectomy . Blood , urine , tissue sample obtain baseline end study treatment correlative laboratory study . Samples evaluate pharmacokinetics polyphenon E use high performance liquid chromatography . Levels epigallocatechin-3-gallate [ EGCG ] catechins find polyphenon E assess correlation serum , urine , tissue . Intermediate endpoint biomarkers evaluate dose-response modulation serum ( i.e. , IGF-1 IGFBP-3 ) via ELISA bladder tissue obtain time bladder surgery ( i.e. , PCNA , MMP2 , clusterin , VEGF , p27 , ODS ) via IHC . Patients University Wisconsin undergo additional biopsy bladder tissue matrix-assisted laser desorption quadrupole time-of-flight ( O-MALDI-qTOF ) analysis EGCG pharmacokinetics . Tissue sample examine intracellular concentration distribution EGCG . Genotyping study pyrosequencing UGT COMT polymorphism also perform .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>Criteria : Diagnosis bladder cancer Bladder tumor discover cystoscopy within past 60 day Invasive noninvasive tumor Primary tumor may represent either initial diagnosis recurrent disease clinical stage No metastatic disease Must eligible candidate partial cystectomy , radical cystectomy , transurethral resection bladder tumor ( TURBT ) Has undergone treatment superficial invasive bladder cancer since diagnostic cystoscopy TURBT radical cystectomy plan curative surgical treatment ECOG performance status ( PS ) 01 OR Karnofsky PS 70100 % More 30 day since prior intravesical therapy adjuvant chemotherapy More 30 day since prior bladder surgery Biopsies consider surgeries No prior pelvic radiotherapy No concurrent systemic chemotherapy cancer , except nonmelanoma skin cancer No concurrent NSAIDs ( e.g. , ibuprofen , naproxen , cyclooxygenase2 inhibitor ) except = &lt; 81 mg aspirin per day Concurrent acetaminophen ( Tylenol ) prescription opioids combine acetaminophen ( i.e. , Percocet , Darvocet , Vicodin , Tylenol # 3 ) allow pain No concurrent investigational agent White Blood Cell ( WBC ) &gt; = 3,000/mm^3 Platelet count &gt; = 100,000/mm^3 Hemoglobin &gt; = 10 g/dL Alkaline phosphatase = &lt; upper limit normal ( ULN ) Bilirubin = &lt; ULN Asparate Aminotransferase ( AST ) Alanine Transaminase ( ALT ) = &lt; ULN Sodium 135144 mmol/L ( inclusive ) Potassium 3.24.8 mmol/L ( inclusive ) Chloride 85114 mmol/L ( inclusive ) Bicarbonate &gt; 11 mEQ/dL Negative pregnancy test Fertile patient must use effective contraception Willing avoid green tea beverage green teacontaining product study participation No evidence cancer , except nonmelanoma skin cancer No history allergic reaction attribute tea compound similar chemical biologic composition Polyphenon E inactive ingredient Polyphenon E capsule No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection , Symptomatic congestive heart failure , Unstable angina pectoris , Cardiac arrhythmia , Psychiatric illness/social situation would limit study compliance More 24 hour since prior concurrent consumption green tea supplement 2 cup ( 16 oz ) green tea either dietary source nutritional supplementation Topical cosmetic ( i.e. , lotion , shampoo , makeup ) contain green tea allow Creatinine normal Not pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>